The continued use of GLP-1 weight loss drugs could cut mortality rates by up to 6.4% by 2045, according to new research spearheaded by Swiss Re. Titled "The future of metabolic health and weight loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results